An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial - 14/12/18
, Eliana Vieira Santucci, BSc a, Lucas Petri Damiani, MHS a, Cecilia Bahit, MD b, Germán Málaga, MD c, Octávio Marques Pontes-Neto, MD, PhD d, Sheila Cristina Ouriques Martins, MD, PhD e, Viviane Flumignan Zétola, MD, PhD f, Karina Normilio-Silva, MSc a, Gabriel Rodrigues de Freitas, MD, PD g, Alessandra Gorgulho, MSc h, Antônio De Salles, MD, PhD h, Beatriz Gonzales Pacheco da Silva, BSc a, Juliana Yamashita Santos, BSc a, Isabella de Andrade Jesuíno, BSc a, Priscila Regina Torres Bueno, MSc a, Alexandre Biasi Cavalcanti, MD, PhD a, Hélio Penna Guimarães, MD, PhD a, Ying Xian, MD, PhD h, Janet Prvu Bettger, ScD h, Renato D. Lopes, MD, PhD i, j, Eric D. Peterson, MD, MPH i, Otávio Berwanger, MD, PhD aAbstract |
Background |
Translating evidence into clinical practice in the management of acute ischemic stroke (AIS) and transient ischemic attack (TIA) is challenging especially in low- and middle-income countries.
Objectives |
The aim of this study is to assess the effect of a multifaceted quality improvement intervention on adherence to evidence-based therapies for AIS and TIA patients care.
Design |
We designed a pragmatic, 2-arm cluster-randomized trial involving 36 clusters and 1624 patients from Brazil, Argentina, and Peru. Hospitals are randomized to receive a multifaceted quality improvement intervention (intervention group) or to routine care (control group). The BRIDGE Stroke multifaceted quality improvement intervention includes case management, reminders, health care providers’ educational materials (including treatment algorithms), interactive workshops, and audit and feedback reports. Primary outcome is a composite adherence score to AIS and TIA performance measures. Secondary outcomes include an “all or none” composite end point to performance measures, the individual components of the composite end points, and clinical outcomes at 90 days following admission (stroke recurrence, death, and disability measured by the modified Rankin scale).
Summary |
The BRIDGE Stroke Trial is an international pragmatic evaluation of a multifaceted quality improvement intervention. If effective, this intervention could be potentially extended widely to improve the quality of care and outcomes of patients with AIS or TIA.
Le texte complet de cet article est disponible en PDF.Plan
| Hector O. Ventura, MD, served as guest editor for this article. |
|
| RCT# NCT02223273 |
Vol 207
P. 49-57 - janvier 2019 Retour au numéro
Article précédent
- Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial
- Maria Julia Machline-Carrion, Rafael Marques Soares, Lucas Petri Damiani, Viviane Bezerra Campos, Bruna Sampaio, Juliana Yamashita, Francisco H. Fonseca, Maria Cristina Izar, Celso Amodeo, Octavio Marques Pontes-Neto, Pedro Gabriel de Melo Barros, Renato D. Lopes, Nilton Brandão da Silva, Hélio Penna Guimarães, Leopoldo Piegas, Airton T. Stein, Otavio Berwanger
- Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study
- Mintu P. Turakhia, Manisha Desai, Haley Hedlin, Amol Rajmane, Nisha Talati, Todd Ferris, Sumbul Desai, Divya Nag, Mithun Patel, Peter Kowey, John S. Rumsfeld, Andrea M. Russo, Mellanie True Hills, Christopher B. Granger, Kenneth W. Mahaffey, Marco V. Perez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?